Nanobiotix S.A. Business Summary

Nanobiotix S.A. (NBTX) is a late-stage clinical biotechnology company that generates revenue primarily through strategic licensing, milestone-based payments, and future royalty streams derived from its proprietary nanoparticle-based therapeutic platforms. The company’s financial model is anchored by a massive global collaboration with Janssen Pharmaceutica NV (a Johnson & Johnson company) for its lead candidate, NBTXR3 (JNJ-1900), a first-in-class radio-enhancer designed to amplify radiotherapy efficacy in solid tumors. This agreement, valued at up to $2.6 billion, provides Nanobiotix with significant development and regulatory milestones, alongside tiered double-digit royalties on net sales. The company operates across three primary business segments: oncology (radiotherapy enhancement), bioavailability and biodistribution, and central nervous system disorders. Within the competitive landscape, Nanobiotix contends with oncology-focused biotech firms such as Agenus, Aura Biosciences, and Amgen; however, it distinguishes itself as a market pioneer in physics-based nanomedicine, offering a unique mechanism of action that physically destroys tumor cells rather than relying on traditional chemical pathways. The company’s leadership is spearheaded by Co-founder and CEO Laurent Levy, PhD, a nanomedicine pioneer with over 20 years of experience in the field, and Co-founder Earl Bergey. The executive team includes Chief Financial and Business Officer Bart Van Rhijn, who joined from Servier Pharmaceuticals to lead global financial strategy, and Chief Medical Officer Louis Kayitalire, MD, who oversees the clinical advancement of the NBTXR3 program. The Supervisory Board is chaired by Gary M. Phillips, MD, and includes notable industry experts such as Dr. Margaret A. Liu and Anat Naschitz. Nanobiotix is backed by high-profile institutional investors and partners, including Johnson & Johnson Innovation (JJDC), Goldman Sachs, and HealthCare Royalty (HCRx), the latter of which recently provided a $71 million royalty monetization deal that extends the company’s cash visibility into early 2028.